Acute Myeloid Leukemia (AML) Research & Clinical Trials

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that affects myeloid cells, which are precursor cells that normally develop into red blood cells, platelets, and certain types of white blood cells. AML is primarily an adult disease, with most cases occurring in people over 65.

Treatment has traditionally relied on intensive chemotherapy, which can be difficult for older patients to tolerate. Recent advances in precision medicine and targeted therapy are transforming AML treatment, offering more effective and better-tolerated options.

Treatment Challenges

• Many patients are older and may not tolerate intensive chemotherapy
• High relapse rates even after initial successful treatment
• Diverse genetic subtypes requiring different approaches
• Need for better treatments for patients who relapse

Recent Advances

The past decade has seen significant AML treatment advances including new targeted drugs, precision medicine approaches, and exploration of immunotherapy. These developments are improving outcomes, particularly for older patients who previously had limited options.